Scott Hensley

Scott Hensley appears in the following:

Nobel Prize goes to scientists who made mRNA COVID vaccines possible

Monday, October 02, 2023

Hungarian-born biochemist Katalin Karikó and American immunologist Drew Weissman found that a chemical change to genetic code called mRNA eliminated a problematic side effect when used in vaccines.

Comment

CDC advisers back broad rollout of new COVID boosters

Tuesday, September 12, 2023

A panel of doctors and scientists advising the Centers for Disease Control and Prevention voted to recommend that people 6 months of age and older get new COVID boosters this fall.

Comment

FDA advisers support approval of RSV vaccine to protect infants

Thursday, May 18, 2023

At least 58,000 childern younger than 5 years old are hospitalized each year with RSV infections. A Pfizer vaccine given to pregnant people could help protect their infants from severe RSV illness.

Comment

FDA advisers narrowly back first gene therapy for muscular dystrophy

Friday, May 12, 2023

A panel of experts voted 8-6 in favor of Food and Drug Administration approval of the first gene therapy for Duchenne muscular dystrophy, a fatal genetic disease.

Comment

Advisers to the FDA back first over-the-counter birth control pill

Wednesday, May 10, 2023

In a unanimous vote, 17-0, a panel of advisers to the Food and Drug Administration recommended that the agency approve the first over-the-counter birth control pill.

Comment

An FDA committee votes to roll out a new COVID vaccination strategy

Thursday, January 26, 2023

Advisers to the U.S. Food and Drug Administration today endorsed a proposal to make big changes in the nation's approach to vaccinating people against COVID-19.

Comment

Two new research papers cast doubt on the new COVID booster

Tuesday, October 25, 2022

Biden received a new COVID booster as part of the administration's push to increase uptake, but two new research papers cast doubt on whether they are any better than the original vaccines.

Comment

FDA authorizes first revamp of COVID vaccines to target omicron

Wednesday, August 31, 2022

The new shots from Moderna and Pfizer-BioNTech target both the original strain of the coronavirus and the omicron BA.4/BA.5 subvariants that most people are catching now.

Comment

Advisers to the FDA back COVID vaccines for the youngest children

Wednesday, June 15, 2022

A committee of experts voted unanimously to recommend that the Food and Drug Administration authorize COVID-19 vaccines from Moderna and Pfizer-BioNTech for children as young as 6-months-old.

Comment

Advisers to the FDA back Novavax COVID vaccine

Tuesday, June 07, 2022

Advisers to the Food and Drug Administration overwhelmingly voted to recommend that it authorize Novavax's two-dose vaccine against COVID-19.

Comment

Advisers to FDA weigh in on updated COVID boosters for the fall

Wednesday, April 06, 2022

The vaccines now in use are based on the form of the virus that circulated at the beginning of the pandemic and are less effective against the omicron variant. New options are in the works.

Comment

Pfizer-BioNTech will seek authorization for second COVID booster for older adults

Tuesday, March 15, 2022

Pfizer and BioNTech are planning to ask the Food and Drug Administration to authorize a second COVID-19 booster shot for people age 65 and older.

Comment

The FDA postpones a highly anticipated meeting on the Pfizer vaccine for young kids

Friday, February 11, 2022

"We believe additional information regarding the ongoing evaluation of a third dose should be considered as part of our decision-making for potential authorization," FDA officials said in a statement.

Comment

The FDA authorizes a Pfizer booster shot for children ages 12 to 15

Monday, January 03, 2022

The authorization comes in the midst of an explosion of COVID-19 cases nationwide driven by the omicron variant — a surge that has brought a spike in pediatric hospitalizations.

Comment

The FDA has authorized Merck's COVID pill for home use — the second in two days

Thursday, December 23, 2021

The medicine, called molnupiravir, is taken twice a day for five days and works by preventing the virus from replicating. Merck says it will have 10 million packs available by the end of the month.

Comment

FDA authorizes 1st antiviral pill for COVID

Wednesday, December 22, 2021

In a highly anticipated decision, the Food and Drug Administration authorized Pfizer's Paxlovid as the first antiviral pill to treat COVID-19 at home.

Comment

CDC narrows use of J&J vaccine due to concerns about rare blood clots

Thursday, December 16, 2021

The agency implemented experts' advice because of a rare and sometimes fatal blood-clotting problem known as TTS. More than 16 million people in the U.S. have received a shot of the J&J vaccine.

Comment

Pfizer data shows that its COVID-19 pill is effective against severe disease

Tuesday, December 14, 2021

The research finds that the medicine, called Paxlovid, was effective in preventing hospitalization and death when taken by people with mild to moderate illness within a few days of symptoms.

Comment

An FDA panel supports Merck COVID drug in mixed vote

Tuesday, November 30, 2021

If the Food and Drug Administration authorizes use of the drug, called molnupiravir, it would be the first oral COVID-19 treatment that could be taken at home.

Comment

CDC backs expansion of COVID boosters for all adults

Friday, November 19, 2021

CDC Director Rochelle Walensky gave the green light to boosters just hours after a panel of vaccine advisors voted unanimously to recommend boosters for anyone 18 and older.

Comment